Craft

Oncosil Medical

Stock Price

$0

2024-10-04

Market Capitalization

$53 M

2024-10-04

Revenue

$1.2 M

FY, 2025

Oncosil Medical Summary

Company Summary

Overview
OncoSil Medical (formerly NeuroDiscovery) is a medical device company focused on localized treatments for patients with pancreatic and liver cancer. It offers OncoSil System, a brachytherapy device that implants a pre-determined dose of beta radiation via injection under endoscopic ultrasound (EUS) guidance. The beta particles emitted by OncoSil travel a short distance in the tissue causing damage to targeted cell DNA, which renders them incapable of further cell division and proliferation.
Type
Public
Status
Active
Founded
2004
HQ
North Sydney, AU | view all locations
Website
https://www.oncosil.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Charles Rowland

    Charles Rowland, President of Us Operations

    • Roger Aston

      Roger Aston, Non Executive Director

      • Martin Cross

        Martin Cross, Non-Executive Director

        LocationsView all

        3 locations detected

        • North Sydney, NSW HQ

          Australia

          suite 402, level 4/50 Berry St

        • North Sydney, NSW

          Australia

          Suite 503, Level 5/15 Blue St

        • Berlin, BE

          Germany

          Pariser Platz 6A

        Oncosil Medical Financials

        Summary Financials

        Revenue (H1, 2026)
        $783.0K
        Gross profit (H1, 2026)
        $1.8M
        Net income (H1, 2026)
        ($4.5M)
        Cash (H1, 2026)
        $2.9M
        EBIT (H1, 2026)
        ($4.6M)

        Footer menu